Populations

Dataset

EPAR TECHNICAL REPORT #393
Publication Date: 11/22/2019
Type: Research Brief
Abstract

While literature on achieving Inclusive Agricultural Transformation (IAT) through input market policies is relatively robust, literature on the effect of output market policies on IAT is rarer. We conduct a selective literature review of output market policies in low- and middle-income countries to assess their influence on IAT and find that outcomes are mixed across all policy areas. We also review indicators used to measure successful IAT,  typologies of market institutions involved in IAT, and agricultural policies and maize yield trends in East Africa. This report details our findings on these connected, yet somewhat disparate elements of IAT to shed more light on a topic that has not been the primary focus of the literature thus far.

EPAR Technical Report #346
Publication Date: 04/23/2018
Type: Literature Review
Abstract

The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.

EPAR Technical Report #239
Publication Date: 08/20/2013
Type: Literature Review
Abstract

This research brief provides an overview of the banana and plantain value chains in West Africa. Because of the greater production and consumption of plantains than bananas in the region, the brief focuses on plantains and concentrates on the major plantain-producing countries of Ghana, Cameroon, and Nigeria. The brief is divided into the following sections: Key Statistics (trends in banana and plantain production, consumption, and trade since 1990), Production, Post-Harvest Practices and Challenges, Marketing Systems, and Importance (including household consumption and nutrition). West Africa is one of the major plantain-producing regions of the world, accounting for approximately 32% of worldwide production. Plantains are an important staple crop in the region with a high nutritional content, variety of preparation methods, and a production cycle that is less labor-intensive than many other crops. In addition to plantains, bananas are also grown in West Africa, but they account for only 2.3% of worldwide production. Bananas are more likely than plantains to be grown for export rather than local consumption. Major constraints to banana and plantain production include pests and disease, short shelf life, and damage during transportation.